Japan Anti-VEGF Market was valued at USD 2.3 Billion in 2022 and is projected to reach USD 3.8 Billion by 2030, growing at a CAGR of 7.0% from 2024 to 2030.
The Japan Anti-VEGF Market: Industry Requirements and Trends
Japan's anti-vascular endothelial growth factor (VEGF) therapeutics market has experienced significant developments in recent years, reflecting both challenges and opportunities for the pharmaceutical industry. Understanding these dynamics is crucial for stakeholders aiming to navigate this evolving landscape effectively.
Market Overview
Market Size and Forecast: In 2024, the Japan anti-VEGF therapeutics market generated a revenue of USD 204.8 million. However, projections indicate a decline, with expectations to reach USD 121.2 million by 2030, corresponding to a compound annual growth rate (CAGR) of -8.9% from 2025 to 2030.
Product Segmentation: Among the available treatments, Eylea emerged as the largest revenue-generating product in 2024. Notably, Beovu is anticipated to be the most lucrative segment, registering the fastest growth during the forecast period.
Industry Requirements and Trends
Innovative Therapeutic Options: The industry is witnessing a push towards novel treatments. For instance, Chugai Pharmaceutical Co., Ltd. filed for an additional indication of Vabysmo for angioid streaks, a leading cause of vision loss. If approved, Vabysmo would be the first product for angioid streaks in Japan, highlighting the industry's commitment to addressing unmet medical needs.
Cost-Effective Solutions: The introduction of biosimilars is gaining traction to alleviate economic burdens. A ranibizumab biosimilar by Senju Pharmaceutical Co., Ltd., approved in September 2021, is expected to reduce costs for patients with neovascular age-related macular degeneration (nAMD) and society at large.
Demographic Considerations: Japan's aging population significantly influences the demand for anti-VEGF therapies. Studies indicate that individuals aged 70 and above account for approximately 80% of anti-VEGF injections, underscoring the need for age-appropriate treatment protocols.
Personal Insights
Reflecting on the industry's trajectory, it's evident that balancing innovation with affordability remains a priority. The shift towards biosimilars and the development of treatments for previously unaddressed conditions demonstrate a responsive and adaptive market. Engaging with healthcare professionals, patients, and policymakers will be essential in shaping a sustainable future for anti-VEGF therapies in Japan.
In conclusion, the Japan anti-VEGF market is at a pivotal juncture, with industry requirements evolving to meet the challenges of an aging population and economic constraints. By focusing on innovative and cost-effective solutions, the industry can continue to provide effective treatments for patients in need.
Get an In-Depth Research Analysis of the Japan Anti-VEGF Market Size And Forecast [2025-2032]
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer
Inc.
Xbrane Biopharma AB
Allergan
Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc. (Mylan)
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Anti-VEGF Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Anti-VEGF Market
Monoclonal Antibodies
Fusion Proteins
Intravitreal Injections
Topical Treatments
Retinal Diseases
Ophthalmic Diseases
Hospitals
Ambulatory Surgical Centers
Eye Clinics
VEGF Inhibition
Angiogenesis Inhibition
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Anti-VEGF Market Research Analysis
1. Introduction of the Japan Anti-VEGF Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Anti-VEGF Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Anti-VEGF Market, By Type
6. Japan Anti-VEGF Market, By Application
7. Japan Anti-VEGF Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Anti-VEGF Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/